文献速递妇产影像介入USMR

超声造影定量子宫肌瘤灌注参数对高强度聚焦超声消融治疗效果的预测价值

Predictive Value of Quantitative Uterine Fibroid Perfusion Parameters From Contrast-Enhanced Ultrasound for the Therapeutic Effect of High-Intensity Focused Ultrasound Ablation.
PubMed 文献 · J Ultrasound Med · 2018-10-04

研究纳入263例单发子宫肌瘤患者,HIFU消融前用超声造影测量到达时间、达峰时间、增强时间、增强强度及增强速率,以治疗后MRI无灌注体积比≥70%或<70%分组,发现无灌注体积比≥70%组到达、达峰、增强时间更长而增强强度与增强速率更低,增强时间、增强强度、增强速率的AUC分别为0.73、0.79、0.81。

要点

  • 治疗前超声造影增强时间、增强强度、增强速率可预测HIFU消融后无灌注体积比是否≥70%,AUC分别为0.73、0.79、0.81。
  • 无灌注体积比≥70%组增强强度29.7±16.7 dB、增强速率3.2±1.5 dB/s,低于<70%组的63.2±26.3 dB、8.6±4.3 dB/s。
  • 无灌注体积比与增强强度(r=-0.631)、增强速率(r=-0.712)负相关,与到达时间(r=0.322)、达峰时间(r=0.456)、增强时间(r=0.477)正相关。

核心结论

  • 超声造影定量参数可能有助于评估子宫肌瘤HIFU消融的治疗效果。

研究设计与样本

  • 共263例单发子宫肌瘤患者在超声引导下接受HIFU消融,治疗前用超声造影评估到达时间、达峰时间、增强时间、增强强度及增强速率,治疗后以MRI无灌注体积比≥70%或<70%分组比较各参数预测消融疗效的性能。

诊断标准与关键数值

  • 以治疗后MRI无灌注体积比≥70%为消融疗效较好组、<70%为较差组;增强时间AUC 0.73、增强强度AUC 0.79、增强速率AUC 0.81(P<.05);无灌注体积比与增强强度(r=-0.631)、增强速率(r=-0.712)负相关,与到达时间(r=0.322)、达峰时间(r=0.456)、增强时间(r=0.477)正相关(P<.05)。

临床应用与阅片要点

  • 治疗前超声造影测量的增强时间、增强强度、增强速率可用于预判HIFU消融后无灌注体积比是否≥70%,其中增强速率AUC最高(0.81)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the predictive significance of quantitative perfusion parameters from contrast-enhanced ultrasound (CEUS) for the therapeutic response to high-intensity focused ultrasound (HIFU) ablation in patients with uterine fibroids.

METHODS: A total of 263 patients with single uterine fibroids were treated with HIFU ablation under ultrasound guidance. The arrival time, peak time, enhancement time, enhancement intensity, and enhancement rate were evaluated with pretreatment CEUS. According to a nonperfused volume ratio evaluation by posttreatment magnetic resonance imaging, all patients were assigned to groups with volume ratios of 70% or higher and lower than 70%. Then the predictive performances of different parameters for ablation efficacy were studied.

RESULTS: The arrival time, peak time, and enhancement time in the group with a nonperfused volume ratio of 70% or higher were longer than those in the group with a volume ratio lower than 70% (mean ± SD, 16.7 ± 3.5, 26.5 ± 4.9, and 10.2 ± 2.6 seconds, respectively, versus 13.3 ± 4.2, 20.8 ± 5.4, and 7.6 ± 2.3 seconds), whereas patients with a volume ratio of 70% or higher had a lower mean enhancement intensity and enhancement rate than those with a volume ratio lower than 70% (29.7 ± 16.7 dB and 3.2 ± 1.5 dB/s versus 63.2 ± 26.3 dB and 8.6 ± 4.3 dB/s; P < .05). The nonperfused volume ratio was negatively correlated with the enhancement intensity and enhancement rate (r = -0.631 and -0.712) but positively correlated with the arrival time, peak time, and enhancement time (r = 0.322, 0.456, and 0.477; P < .05). The areas under the receiver operating characteristic curve for the enhancement time, enhancement intensity, and enhancement rate were 0.73, 0.79, and 0.81 (P < .05).

CONCLUSIONS: Quantitative parameters from CEUS are potentially useful for evaluating the therapeutic effect of HIFU ablation for uterine fibroids.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Wang YJ, Zhang PH, Zhang R, et al. Predictive Value of Quantitative Uterine Fibroid Perfusion Parameters From Contrast-Enhanced Ultrasound for the Therapeutic Effect of High-Intensity Focused Ultrasound Ablation. J Ultrasound Med. 2018. PMID: 30286521. doi:10.1002/jum.14838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。